A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)
CompletedCTIS2024-513143-82-00
AstraZeneca ABHeart failure with reduced ejection fraction, Renal impairment
Start: 2024-10-15End: 2025-08-21Target: 12Updated: 2025-02-11